By Gabriel García March 26, 2024
In a significant step towards researching the therapeutic effects of psychedelics, Israel has joined the international scene through a pioneering collaboration between Optimi Health Corp. and the Institute for Psychedelic Research at Tel Aviv University (IPR-TLV). This partnership marks Optimi’s foray into the Israeli psychedelic market and promises to contribute to the advancement of knowledge in the field of mental health and addiction.
In this collaboration, Optimi will supply MDMA to the IPR-TLV to support research on the effects of this compound in animal models of alcohol addiction. This study, scheduled to begin in the summer of 2024 and conclude by the end of 2025, represents a joint commitment to explore the therapeutic potential of MDMA in a clinical and research context.
MDMA, produced in-house by Optimi, will be supplied to the IPR-TLV as an active pharmaceutical ingredient (API), demonstrating Optimi’s commitment to quality and safety standards in psychedelic research. Obtaining import permits from IPR-TLV and export permits from Health Canada paves the way for the development of this ground-breaking study.
Bill Ciprick, CEO of Optimi, expressed his enthusiasm for this collaboration, stating: “Our agreement with IPR-TLV marks an exciting entry for Optimi into the Israeli psychedelic research market. We are delighted to expand our reach as a leading provider of psychedelics, ensuring that researchers around the world turn to us for their clinical and research needs.”
The IPR-TLV represents a visionary initiative in Israel, dedicated to advancing interdisciplinary research on psychedelics in the context of brain-mind-body associations. As the first institute of its kind in Israel, the IPR-TLV aims to establish itself as a world leader in neuroscience research on psychedelics and psychoactive medicine.
This collaboration comes at a time when research on psychedelics is gaining momentum worldwide, with growing interest in the potential therapeutic benefits of these substances in the treatment of various mental conditions and addictions.
Those interested in exploring the topic of psychedelics further can find valuable resources in the ‘Psychonaut’s Guides’ series of books, which offer an informative and thoughtful perspective on the responsible and therapeutic use of psychedelics. These books can be an excellent introduction for those who wish to better understand the potential of these substances and their impact on mental health and well-being.
With this collaboration between Optimi Health Corp. and IPR-TLV, Israel joins the growing global community of psychedelic researchers and advocates, paving the way for greater understanding and application of these substances in the medical and therapeutic realm.
If you are interested in learning more about this exciting world, we invite you to consult the Psychonaut’s Guides by Argonowta. These books will give you a broad and balanced view of psychedelics and their potential therapeutic effects. Remember, however, that these substances are not a panacea or a magic solution to all your problems. Their use requires professional guidance, an appropriate context and a responsible attitude. Psychedelics can be a powerful tool for personal change, but they can also be dangerous if used inappropriately or irresponsibly.
The Psychonaut’s Guides from Argonowta Publishing is a collection of books that explain in a rigorous and accessible way the scientific, historical, cultural and experiential aspects of psychedelic substances. These guides offer updated and contrasted information on the therapeutic and neuroscientific applications of psilocybin, LSD, DMT and MDMA, as well as practical advice on how to prepare, carry out and take advantage of psychedelic experiences. The Psychonaut’s Guides are a must-have reference for anyone interested in learning about the psychedelic renaissance that is transforming mental health and changing lives.
Take a look at our social networks to keep updated:
